Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

HCV Notes: NICE Nod To Gilead's Epclusa; Achillion, AbbVie Data Updates

Executive Summary

The UK's health care cost-assessment body finds Gilead's newest combo, Epclusa, cost-effective in most HCV settings. J&J/Achillion now have 12-week SVR data for six-week treatment regimen, and AbbVie builds support for an eight-week regimen for Viekirax.

You may also be interested in...



J&J, Achillion Could Set Six-Week Treatment Paradigm In HCV

Interim Phase IIa data of a triple combination from J&J and Achillion shows 100% SVR at end of treatment with a six-week dosing regimen. No currently approved HCV therapy has such a short treatment duration.

NICE Backs Hep C Drug Zepatier After Merck Offers Price Discount

UK HTA gives provisional backing to Merck’s once-daily fixed-dose hepatitis C combo Zepatier after the US drug maker offers an undisclosed price cut.

Gilead's Epclusa And Merck's Zepatier Hep C Combos Get EMA backing

Gilead's sofosbuvir/velpatasvir combination Epclusa and Merck's grazoprevir and elbasvir combo Zepatier are on course for approval in Europe for treating hepatitis C, but analysts say Gilead's two-drug therapy has the better commercial prospects of the two.

Topics

Related Companies

UsernamePublicRestriction

Register

SC097356

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel